Investigational drug · Phase 2
SPY002-072
Also called: SPY072
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SPY002-072"
First trial start
2025
Aug 21, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPY002-072", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Rheumatic Diseases
- Rheumatic Joint Disease
- PsA (Psoriatic Arthritis)
- AxSpA
- Rheumatologic Disease
- Hidradenitis Suppurativa (HS)
Approved drugs for the same conditions: Rheumatoid arthritis · Psoriatic arthritis · Ankylosing spondylitis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SPY002-072" as an intervention, largest first.
- A Study of SPY072 in Rheumatic DiseasePivotal-lookingActive, not recruiting
Spyre Therapeutics, Inc.Industry
NCT07148414 · 285 participants (planned) · Start Aug 21, 2025 · Primary completion Oct 31, 2026
Drug: SPY002-072; Placebo · For: Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis and 5 more
Sites: Avondale, Arizona; Tucson, Arizona; Chula Vista, California · 64 sites in all
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)Pivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07766005 · 150 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 2027
Drug: SPY072; Placebo and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Rogers, Arkansas; Irvine, California · 34 sites in all
Spyre Therapeutics, Inc.Industry
NCT06622070 · 40 participants · Start Nov 18, 2024 · Primary completion Jul 28, 2026
Drug: SPY002-072 · For: Healthy
Sites: Cypress, California; Montreal, Canada
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.